Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its earnings results on Thursday, August, 3rd. The company reported $4.17 EPS for the quarter, beating the Zacks' consensus estimate of $2.67 by $1.50. The company earned $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals's quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.82 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

25 brokerages have issued 1 year price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $345.00 to $605.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $492.82 in the next twelve months. View Analyst Ratings for Regeneron Pharmaceuticals.

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Regeneron’s second-quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share. Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The increase in guidance was also encouraging. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and the company is working to expand its label. A potential approval of the drug in the EU in the second half will further boost sales. Further, the approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU has boosted the company’s portfolio. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress." (8/9/2017)
• 2. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
• 3. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
• 4. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)

Some companies that are related to Regeneron Pharmaceuticals include Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Axovant Sciences Ltd (AXON), China Biologic Products (CBPO) and Prothena Corporation PLC (PRTA).

Regeneron Pharmaceuticals' management team includes the folowing people:

• P. Roy Vagelos M.D., Chairman of the Board
• Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
• Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
• Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
• Neil Stahl Ph.D., Executive Vice President - Research and Development
• Robert J. Terifay, Executive Vice President - Commercial
• Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
• Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
• Peter Powchik M.D., Senior Vice President - Clinical Development
• George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Regeneron Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.67%), Capital World Investors (6.54%), BlackRock Inc. (5.86%), Vanguard Group Inc. (4.99%), State Street Corp (3.10%) and Artisan Partners Limited Partnership (1.86%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Capital World Investors, Bank of New York Mellon Corp, State Street Corp, Manning & Napier Advisors LLC, BB Biotech AG, Ameriprise Financial Inc. and Rockefeller Financial Services Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, FMR LLC, TIAA CREF Investment Management LLC, PointState Capital LP, Vanguard Group Inc., Teachers Advisors LLC and Polen Capital Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $431.38.